Preclinical Alzheimer's disease represents the phase where the brain undergoes changes associated with Alzheimer's, such as the formation of amyloid plaques and tau tangles, well before any symptoms are evident. During this period, individuals typically do not exhibit noticeable cognitive decline, although minor alterations in memory or thinking may occur. Identifying preclinical Alzheimer's often involves advanced biomarker tests, including PET scans and cerebrospinal fluid analysis, to detect these early pathological changes. Recognizing this stage is essential for the development of interventions aimed at delaying or preventing the onset of symptomatic Alzheimer's. Early identification enables proactive measures, such as lifestyle modifications and participation in clinical trials, offering a proactive approach to managing and potentially altering the disease's trajectory.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China